Helus Pharma Announces Completion of Legal Name Change
Key Highlights
- ➤Legal name changed from Cybin Inc. to Helus Pharma Inc. effective October 1, 2026
- ➤Shares continue trading on Nasdaq and Cboe Canada under ticker HELP
- ➤HLP003 is in Phase 3 development for adjunctive major depressive disorder treatment
- ➤HLP003 received Breakthrough Therapy Designation from the U.S. FDA
NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the Company’s legal name has been changed from “Cybin Inc.” to “Helus Pharma Inc.” effective October 1, 2026. The name change was approved by shareholders at the Company’s annual and special meeting of shareholders held on September 22, 2026. The name change follows the Company’s adoption of the business name “Helus Pharma” on January 5, 2026 and reflects the Company’s anticipated transformation from a clinical stage discovery and development company to a commercial-ready pharmaceutical company.
The Company’s common shares will continue to trade on the Nasdaq Global Market and Cboe Canada under the ticker symbol “HELP”. No action is required by existing shareholders, and outstanding share certificates and DRS statements remain valid. The new CUSIP number assigned to the Company’s common shares is 423492107 and its new ISIN is CA4234921076.
Get started
Create a free account to read the full story.